Evidence map›Paper›PMID 26790099›Full record

ArticlePloS one2016

Functional Impact of Corticotropin-Releasing Factor Exposure on Tau Phosphorylation and Axon Transport.

Michelle H Le, April M Weissmiller, Louise Monte, Po Han Lin, Tia C Hexom, Orlangie Natera, Chengbiao Wu, Robert A Rissman

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Brain Under Stress and Alzheimer's Disease.Cellular and molecular neurobiology · 2018
    Review
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Michelle H LeDepartment of Neurosciences, University of California San Diego, La Jolla, CA 92093, United States of America.
April M WeissmillerDepartment of Neurosciences, University of California San Diego, La Jolla, CA 92093, United States of America.
Louise MonteDepartment of Neurosciences, University of California San Diego, La Jolla, CA 92093, United States of America.
Po Han LinDepartment of Neurosciences, University of California San Diego, La Jolla, CA 92093, United States of America.
Tia C HexomDepartment of Neurosciences, University of California San Diego, La Jolla, CA 92093, United States of America.
Orlangie NateraDepartment of Neurosciences, University of California San Diego, La Jolla, CA 92093, United States of America.
Chengbiao WuDepartment of Neurosciences, University of California San Diego, La Jolla, CA 92093, United States of America.
Robert A RissmanDepartment of Neurosciences, University of California San Diego, La Jolla, CA 92093, United States of America.
University of California, San Diego · US

Funding

TRIAL OF VALPROATE TO ATTENUATE THE PROGRESSION OF ADU01AG010483 · NIA · UNIVERSITY OF ROCHESTER · PI AISEN, PAUL S. · 1991 to 2012
$116.2M
RECRUITMENT COREU19AG010483 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FELDMAN, HOWARD · 2013 to 2020
$80.6M
VIRUS-INDUCED BRAIN PATHOLOGYP50AG005131 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHUN, JEROLD · 1985 to 2018
$55.4M
Center for Protein Folding Machinery (RMI)PN2EY016525 · NEI · BAYLOR COLLEGE OF MEDICINE · PI CHIU, WAH · 2005 to 2015
$33.6M
Neurosciences Graduate Training ProgramT32NS061847 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Brenda L Bloodgood · 2008 to 2026
$7.7M
Stress and CRF Signaling in Alzheimer?s Disease PathogenesisR01AG032755 · NIA · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI RISSMAN, ROBERT, SAWCHENKO, PAUL E. · 2008 to 2012
$1.9M
Polytherapy for AD: Combining Gamma-secretase Modulation and CRFR1 AntagonismR21AG047484 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI RISSMAN, ROBERT, WAGNER, STEVEN LEE · 2014 to 2015
$419k
Validation Studies of CRF Receptor 1 as a Target for ADI01BX003040 · VA · VA SAN DIEGO HEALTHCARE SYSTEM · PI RISSMAN, ROBERT · 2016 to 2020
–
BLRD VA BX003040BLRD VA I01 BX003040NEI NIH HHS PN2 EY016525NIA NIH HHS AG005131NIA NIH HHS AG010483NIA NIH HHS AG032755NIA NIH HHS AG047484NIA NIH HHS P50 AG005131NIA NIH HHS R01 AG032755NIA NIH HHS R21 AG047484NIA NIH HHS U01 AG010483NINDS NIH HHS T32 NS061847
6 · The paper itself

Abstract

Stress exposure or increased levels of corticotropin-releasing factor (CRF) induce hippocampal tau phosphorylation (tau-P) in rodent models, a process that is dependent on the type-1 CRF receptor (CRFR1). Although these preclinical studies on stress-induced tau-P provide mechanistic insight for epidemiological work that identifies stress as a risk factor for Alzheimer's disease (AD), the actual impact of stress-induced tau-P on neuronal function remains unclear. To determine the functional consequences of stress-induced tau-P, we developed a novel mouse neuronal cell culture system to explore the impact of acute (0.5hr) and chronic (2hr) CRF treatment on tau-P and integral cell processes such as axon transport. Consistent with in vivo reports, we found that chronic CRF treatment increased tau-P levels and caused globular accumulations of phosphorylated tau in dendritic and axonal processes. Furthermore, while both acute and chronic CRF treatment led to significant reduction in CREB activation and axon transport of brain-derived neurotrophic factor (BDNF), this was not the case with mitochondrial transport. Acute CRF treatment caused increased mitochondrial velocity and distance traveled in neurons, while chronic CRF treatment modestly decreased mitochondrial velocity and greatly increased distance traveled. These results suggest that transport of cellular energetics may take priority over growth factors during stress. Tau-P was required for these changes, as co-treatment of CRF with a GSK kinase inhibitor prevented CRF-induced tau-P and all axon transport changes. Collectively, our results provide mechanistic insight into the consequences of stress peptide-induced tau-P and provide an explanation for how chronic stress via CRF may lead to neuronal vulnerability in AD.

Indexed as

Stress, PsychologicalAnimalsAxonal TransportBrain-Derived Neurotrophic FactorCells, CulturedCorticotropin-Releasing HormoneCRF Receptor, Type 1FemaleHippocampusMiceMice, Inbred C57BLNeuronsPhosphorylationReceptors, Corticotropin-Releasing Hormonetau ProteinsBrain-Derived Neurotrophic FactorCorticotropin-Releasing HormoneCRF Receptor, Type 1Receptors, Corticotropin-Releasing Hormonetau Proteins

Identifiers

PMID26790099
PMCPMC4720402
OpenAlexW2315072061

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.